Agreement between Georg-August-Univesität Göttingen and global player from Finland Stora Enso Oyj for a new wood/timber treatment

Göttingen, 17.01.2018

MBM ScienceBridge GmbH negotiates exploitation agreement between Georg-August-Univesität Göttingen and global player from Finland Stora Enso Oyj for a new wood/timber treatment to improve its quality developed by Göttinger scientists under the lead of Prof. Dr. Militz.

Through the commercial exploitation agreement, which has been successfully negotiated by MBM ScienceBridge GmbH, the Georg-August-Universität Göttingen will receive financial payments for the benefit for further research and of the researches.

Göttingen tissue engineering enables drug screening thanks to new production methods

Göttingen, 04.10.2019

MBM ScienceBridge GmbH has successfully negotiated an extension of the existing license agreement between the Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (UMG) and the Göttingen-based biotech company Tissue Systems Holding GmbH on the extended commercial use of culturing methods for standardized production of human micro tissues and stem cell-based cells. The technologies are based on the scientific achievements in the field of stem cell based tissue engineering and laboratory automation of the research team led by Prof. Dr. Wolfram-Hubertus Zimmermann, Director of the Institute of Pharmacology and Toxicology at the University Medical Center of Göttingen. The extended exclusive license agreement provides for one-time payments and, in addition to sales-related license fees, an annual minimum license fee.
Nowadays, search for suitable drug candidates and risk assessments are mainly carried out using cell cultures and animal models. However, these models have limited significance for the human organism. The lack of organ physiologiology and functional maturity in standard cell cultures is a challenge that needs to be overcome. "The key to drug development are models based on tissue engineering with functional properties that are characteristic for health and disease. The platforms developed at UMG are aimed at the highest degree of functional maturation. They enable detailed impact analyses and a rational dosage strategy for early clinical studies", says Prof. Zimmermann.

Myoelectric prosthesis control with several degrees of freedom

Göttingen, 09.01.2018

MBM ScienceBridge GmbH successfully negotiates an exploitation agreement for a prosthesis steering control system between the University Medical Center Göttingen and the global player Otto Bock HealthCare GmbH

The prosthesis control involves a multi-functional limb movement auxiliary device and a steering method based on combined estimation regimes of multiple degrees of freedom. This allows a fluent, almost natural movement of the prosthesis. The system including sensors, analysis unit and stimulation unit are contained in the prosthesis. No surgery is required. Otto Bock receives the exclusive rights for commercial exploitation The University and their scientists receive finantial payments in return.

Therapy  for deafness

Göttingen, August 2017

MBM ScienceBridge GmbH successfully negotiates a commercial agreement between the Medical Faculty of the Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (Universitätsmedizin Göttingen, UMG) and Akouos, Inc.